These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo. Li S; Li C; Jin S; Liu J; Xue X; Eltahan AS; Sun J; Tan J; Dong J; Liang XJ Biomaterials; 2017 Nov; 144():119-129. PubMed ID: 28834763 [TBL] [Abstract][Full Text] [Related]
8. Activity of TER286 against human tumor colony-forming units. Izbicka E; Lawrence R; Cerna C; Von Hoff DD; Sanderson PE Anticancer Drugs; 1997 Apr; 8(4):345-8. PubMed ID: 9180387 [TBL] [Abstract][Full Text] [Related]
9. Phosphono analogs of glutathione: inhibition of glutathione transferases, metabolic stability, and uptake by cancer cells. Kunze T; Heps S Biochem Pharmacol; 2000 Apr; 59(8):973-81. PubMed ID: 10692562 [TBL] [Abstract][Full Text] [Related]
10. Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death. Singh S Cancer Chemother Pharmacol; 2015 Jan; 75(1):1-15. PubMed ID: 25143300 [TBL] [Abstract][Full Text] [Related]
12. In vivo characterization and modulation of the glutathione/glutathione S-transferase system in cancer patients. Mulders TM; Keizer HJ; Breimer DD; Mulder GJ Drug Metab Rev; 1995; 27(1-2):191-229. PubMed ID: 7641576 [No Abstract] [Full Text] [Related]
13. Glutathione and cellular resistance to anti-cancer drugs. Hedley D; Chow S Methods Cell Biol; 1994; 42 Pt B():31-44. PubMed ID: 7533246 [No Abstract] [Full Text] [Related]
14. Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies. Rosen LS; Brown J; Laxa B; Boulos L; Reiswig L; Henner WD; Lum RT; Schow SR; Maack CA; Keck JG; Mascavage JC; Dombroski JA; Gomez RF; Brown GL Clin Cancer Res; 2003 May; 9(5):1628-38. PubMed ID: 12738715 [TBL] [Abstract][Full Text] [Related]
15. Glutathione Dong SC; Sha HH; Xu XY; Hu TM; Lou R; Li H; Wu JZ; Dan C; Feng J Drug Des Devel Ther; 2018; 12():3535-3547. PubMed ID: 30425455 [TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies. Rosen LS; Laxa B; Boulos L; Wiggins L; Keck JG; Jameson AJ; Parra R; Patel K; Brown GL Clin Cancer Res; 2004 Jun; 10(11):3689-98. PubMed ID: 15173075 [TBL] [Abstract][Full Text] [Related]
17. gamma-Glutamyl transpeptidase, a glutathionase: its expression and function in carcinogenesis. Hanigan MH Chem Biol Interact; 1998 Apr; 111-112():333-42. PubMed ID: 9679564 [TBL] [Abstract][Full Text] [Related]
18. Clinical reversal of drug resistance. Goldstein LJ Curr Probl Cancer; 1995; 19(2):65-124. PubMed ID: 7600845 [TBL] [Abstract][Full Text] [Related]
19. [Cytotoxic Agents and Immune Checkpoint Inhibitors]. Kawazoe A; Shitara K Gan To Kagaku Ryoho; 2017 Sep; 44(9):717-721. PubMed ID: 28912395 [TBL] [Abstract][Full Text] [Related]
20. Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes. Mahadevan D; Sutton GR Expert Opin Investig Drugs; 2015 May; 24(5):725-33. PubMed ID: 25724698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]